CBD Research
New CBD related research continues to be published and peer reviewed. Below you will find a wealth of abstracts and publications, many provided online by the U.S. National Library of Medicine.
Although all mammals have cell receptors that respond to cannabinoid compounds, data from animal experiments and other preclinical research cannot necessarily be applied to humans. You draw your own conclusions from the research presented.
- Safety and side effects of cannabidiol
- CBD: From an inactive cannabinoid to a drug with wide spectrum of action
- CBD as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
- CBD: An overview of some pharmacological aspects
- CBD: An overview of some chemical and pharmacological aspects
- The endocannabinoid system as an emerging target of pharmacotherapy
- Therapeutic potential of cannabinoid-based drugs
- Targeting the endocannabinoid system with cannabinoid receptor agonists
- Cannabis-based medicines–GW pharmaceuticals
- The therapeutic potential of cannabis and cannabinoids
- Emerging strategies for exploiting cannabinoid receptor agonists as medicines
- Therapeutic potential of cannabinoid-based drugs
- Cannabinoids in clinical practice
- Cannabinoids
- Pharmacology of cannabinoids
- Combined cannabinoid therapy via an oromucosal spray
- Non-psychotropic plant cannabinoids
- Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology
- Care and feeding of the endocannabinoid system
- Understanding the molecular aspects of THC and CBD as antioxidants
- A tale of two cannabinoids
- Clinical Studies With Cannabis and Cannabinoids, 2005-2009
- The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content
- CBD as a Treatment for Acne?
- CBD exerts sebostatic and antiinflammatory effects on human sebocytes
- The endocannabinoid system of the skin in health and disease
- Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling
- Endocannabinoid signaling and epidermal differentiation
- Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
- The therapeutic potential of the endocannabinoid system for Alzheimer’s disease
- Endocannabinoid signalling in Alzheimer’s disease
- A molecular link between the active component of marijuana and Alzheimer’s disease pathology
- Neuroprotective effect of CBD… on beta-amyloid-induced toxicity in PC12 cells
- The Potential Therapeutic Effects of THC on Alzheimer’s Disease
- The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer’s Disease
- Cannabinoids for the treatment of dementia
- CBD in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression
- CBD: A promising drug for neurodegenerative disorders?
- Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer’s disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition
- The role of the endocannabinoid system in Alzheimer’s disease
- The role of phytochemicals in the treatment and prevention of dementia
- Cannabinoids for the treatment of dementia
- Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+ Cells Through PPARγ Involvement
- Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
- CBD as an anxiolytic drug
- Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis Sativa
- CBD reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients
- Neural basis of anxiolytic effects of CBD in generalized social anxiety disorder
- Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
- Effects of CBD on regional cerebral blood flow
- The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
- The anxiolytic effect of CBD on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
- Plant-based medicines for anxiety disorders, part 2
- Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
- Involvement of the endocannabinoid system in osteoarthritis pain
- The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55
- Endocannabinoid Signaling in Autism
- Mutations found in individuals with autism interfere with endocannabinoid signaling in the brain
- Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders
- A novel approach to the symptomatic treatment of autism
- Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders
- Targeting the endocannabinoid system in the treatment of fragile X syndrome
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
- Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
- Marijuana extract helps prevent chemo pain
- CBD in inflammatory bowel diseases: a brief overview
- Cannabis finds its way into treatment of Crohn’s disease
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- The effects of Delta-tetrahydrocannabinol and CBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
- Cannabinoids and the gut: New developments and emerging concepts
- Endocannabinoids and the gastrointestinal tract
- Cannabinoids and gastrointestinal motility: Animal and human studies
- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
- Endocannabinoid system dysfunction in mood and related disorders
- Antidepressant-Like and Anxiolytic-Like Effects of CBD
- The endocannabinoid system and the treatment of mood and anxiety disorders
- Endocannabinoid signaling in the etiology and treatment of major depressive illness
- Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors
- Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants
- Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa
- Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress
- Serum contents of endocannabinoids are correlated with blood pressure in depressed women
- The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants
- Antidepressants and Changes in Concentration of Endocannabinoids and N-Acylethanolamines in Rat Brain Structures
- CBD for children with Dravet’s and intractable seizures (Video)
- Report of a parent survey of CBD-enriched cannabis use in pediatric treatment-resistant epilepsy
- Medicinal marijuana stops seizures, brings hope to a little girl
- Cannabinoids for epilepsy
- Cannabis, CBD, and epilepsy – From receptors to clinical response
- The non-psychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability
- Chronic administration of CBD to healthy volunteers and epileptic patients
- Endocannabinoid system protects against cryptogenic seizures
- Seizing an opportunity for the endocannabinoid system
- Cannabidiol: promise and pitfalls
- Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and otherneuropsychiatricdisorders
- Report of a parent survey of cannabidiol-enriched cannabis use in pediatrictreatment-resistant epilepsy
- From the Editors: Cannabidiol and medical marijuana for the treatment of epilepsy
- Cannabidivarin (CBDV) suppressespentylenetetrazole (PTZ)-inducedincreases in epilepsy-related gene expression
- CBD exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
- Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
- Hypnotic and antiepileptic effects of CBD
- The cannabinoids as potential antiepileptics
- Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats
- Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
- The endocannabinoid system: an emerging key player in inflammation
- Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice
- Cannabinoids, endocannabinoids, and related analogs in inflammation
- Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis
- Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
- Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement
- Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
- Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
- Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death
- Cannabinoids in clinical practice
- Cannabidiol in inflammatory bowel diseases: A brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Cannabinoid actions at TRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
- Therapeutic potential of cannabinoid-based drugs
- Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
- CBD and the gut: New developments and emerging concepts
- Endocannabinoids and the gastrointestinal tract
- CBD and gastrointestinal motility
- Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
- Effects of anandamide in migraine: data from an animal model
- Cannabinoids and hallucinogens for headache
- The endocannabinoid system and migraine
- Variations in the cannabinoid receptor 1 gene predispose to migraine
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
- The endocannabinoid system & the treatment of mood and anxiety disorders
- The endocannabinoid system & psychiatric disorders
- The endocannabinoid system in the regulation of emotions throughout lifespan: A discussion on therapeutic perspectives
- Endocannabinoid system dysfunction in mood and related disorders
- Effects of CBD on regional cerebral blood flow
- Sativex for the management of multiple sclerosis symptoms
- THC & CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis
- Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity
- CBD provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
- Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis
- A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain
- Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain
- Cannabis, pain, and sleep: Sativex Clinical Trials
- Sativex successfully treats neuropathic pain characterised by allodynia: clinical trial
- Cannabinoids for neuropathic pain
- Neuropathic orofacial pain: Cannabinoids as a therapeutic avenue
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
- Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain
- Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes
- Cannabinoids in the management of difficult to treat pain
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain
- Marijuana extract helps prevent chemo pain
- Pot users less likely to take painkillers
- CBD Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts
- Cannabinoid receptors as target for treatment of osteoporosis: A tale of two therapies
- Cannabinoids and bone: Friend or foe?
- Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells
- Cannabinoids and the skeleton: From marijuana to reversal of bone loss
- The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy
- The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption
- Endocannabinoids and the regulation of bone metabolism
- Cannabinoid receptors and the regulation of bone mass
- Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health
- Peripheral cannabinoid receptor, CB2, regulates bone mass
- Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
- Long-chain polyunsaturated fatty acids may mutually benefit both obesity and osteoporosis
- Skeletal lipidomics: Regulation of bone metabolism by fatty acid amide family
- the endocannabinoid system provides an avenue for evidence-based treatment development for ptsd
- Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks
- Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear
- Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid Receptors
- CBD blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
- Stress switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD to LTP in the bed nucleus of the stria terminalis
- Mitigation of post-traumatic stress symptoms by Cannabis resin: A review of the clinical and neurobiological evidence
- Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment
- The endocannabinoid system and extinction learning
- A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers
- Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit
- Non-antidepressant long-term treatment in post-traumatic stress disorder
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system
- Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
- CBD exerts sebostatic and antiinflammatory effects on human sebocytes
- The endocannabinoid system of the skin in health and disease
- Epigenetic control of skin differentiation genes by phytocannabinoids
- A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ
- Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1
- Cannabinoid 1 receptors in keratinocytes modulate proinflammatory chemokine secretion and attenuate contact allergic inflammation
- Attenuation of allergic contact dermatitis through the endocannabinoid system
- Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus
- The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent
- Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex
- Effects of acute systemic administration of CBD on sleep-wake cycle in rats
- Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults
- CBD modulates sleep in rats
- Endocannabinoid modulation of cortical up-states and NREM sleep
- Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat
- Endogenous cannabinoid signaling is essential for stress adaptation
- Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders
- Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output
- Neuromodulators, stress and plasticity: a role for endocannabinoid signalling
- Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress
- Endocannabinoids and stress
- Stress regulates endocannabinoid-CB1 receptor signaling
- Chronic Stress Impairs α1-Adrenoceptor-Induced Endocannabinoid-Dependent Synaptic Plasticity in the Dorsal Raphe Nucleus
- Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance
- Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression
- Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory
- The anxiolytic effect of CBD on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
- Low-frequency stimulation evokes serotonin release in the nucleus accumbens and induces long-term depression via production of endocannabinoid